title: Update on TNF Inhibitors.
abstract: The introduction of tumor necrosis factor (TNF)-α inhibitors dramatically improved the management of psoriasis. Some newer or investigational biologics with different mechanisms of action have demonstrated noninferiority or superiority to etanercept, the first self-injectable anti-TNF-α agent to become available in the United States. Nonetheless, TNF-α inhibitors are likely to remain a mainstay of therapy for many years.
authors.affiliation: Director of Inpatient Dermatology Larkin Community Hospital Professor and Vice Chair Department of Dermatology Herbert Wertheim College of Medicine Florida International University Miami, Florida.
authors.forename: Francisco A
authors.initials: FA
authors.lastname: Kerdel
mesh_terms: D000068879:Adalimumab / Q000008:administration & dosage*; D000911:Antibodies, Monoclonal / Q000008:administration & dosage*; D061067:Antibodies, Monoclonal, Humanized / Q000008:administration & dosage; D015535:Arthritis, Psoriatic / Q000188:drug therapy; D002318:Cardiovascular Diseases / Q000517:prevention & control; D000068582:Certolizumab Pegol / Q000008:administration & dosage*; D002986:Clinical Trials as Topic; D017326:Clinical Trials, Phase III as Topic; D003879:Dermatologic Agents / Q000008:administration & dosage* / Q000009:adverse effects; D000068800:Etanercept / Q000008:administration & dosage*; D006801:Humans; D000069285:Infliximab / Q000008:administration & dosage*; D010880:Piperidines / Q000008:administration & dosage; D011565:Psoriasis / Q000188:drug therapy*; D011743:Pyrimidines / Q000008:administration & dosage; D011758:Pyrroles / Q000008:administration & dosage; D016896:Treatment Outcome; D014409:Tumor Necrosis Factor-alpha / Q000037:antagonists & inhibitors*; D000069549:Ustekinumab / Q000008:administration & dosage
chemical_list: D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D003879:Dermatologic Agents; D010880:Piperidines; D011743:Pyrimidines; D011758:Pyrroles; D014409:Tumor Necrosis Factor-alpha; C000588857:guselkumab; C479163:tofacitinib; C529000:golimumab; D000069285:Infliximab; C549079:ixekizumab; C555450:secukinumab; D000069549:Ustekinumab; D000068879:Adalimumab; D000068800:Etanercept; D000068582:Certolizumab Pegol
keywords: Efficacy; investigational agents; psoriasis; psoriatic arthritis; safety; tumor necrosis factor inhibitors